Business
AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis
AEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis.
About this update from Aeolus Pharmaceuticals Inc
[{"type":"text","content":"\nAEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis\n\nAEOL 20415 Protects Lungs Against Infection in Animal Model of Cystic Fibrosis\n\nMISSION VIEJO, CA--(Marketwired - March 15, 2017) - TREATMENT WITH AEOL 20415 REDUCED INFECTION, IMPROVED BODY WEIGHT AND REDUCED PRESENCE OF WHITE BLOOD CELLS, MACROPHAGES AND LYMPHOCYTESDETAILED RESULTS TO BE SUBMITTED FOR PUBLICATION Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against fibrosis, inflammation, nerve damage and infection announced that a study completed at National Jewish Health showed that AEOL 20415 protects the lungs in a mouse model of cystic fibrosis. The studies were performed by Brian Day, PhD, Vice Chair of Research at National Jewish Health. Aeolus is a biotechnology company focused on developing compounds to address unmet medical needs in both traditional as well as governmental markets. AEOL 20415 has demonstrated potential as both a treatment for cystic fibrosis as well as antibiotic-resistant bacteria. Development of novel treatments for antibiotic-resistant bacteria has been a major priority at both the National Institutes of Health (\"NIH\") and the Biomedical Advanced Research and Development Authority (\"BARDA\"). \"This study confirms previous in-vitro studies indicating that AEOL 20415 is unique because it augments the body's natural host defense system for fighting bacterial infection while limiting inflammation,\" stated Brian Day, PhD, Vice Chair of Research at National Jewish Health. \"Currently available anti-inflammatory drugs work by suppressing the immune system, which can be counterproductive during active infection. AEOL 20415 has demonstrated efficacy in killing drug resistant clinical strains of Burkholderia cepacia and Pseudomonas aeruginosa isolated from cystic fibrosis patients and improving bacterial clearance while diminishing lung inflammation.\"Aeolus believes that AEOL 20415 may have applications as a broad spectrum anti-microbial and in several large medical indications. As an anti-microbial, the compound has demonstrated the ability to kill pathogens, including antibiotic-resistant strains, while dampening inflammation caused by immune response to both viral and bacterial infections. In some infectious diseases, such as virulent strains of influenza viru...